UserGems
+4%
est. 2Y upside i
Pipeline generation platform tracking job changes of past customers
Rank
#2723
Sector
Sales Intelligence
Est. Liquidity
~4Y
Data Quality
Data: LowExpected upside over 2 years is only ~4%, with low confidence due to a stale 2021 Series A valuation and high uncertainty.
Last updated: July 3, 2026
Multiple expands to 10x forward revenue on IPO excitement or acquisition interest, implying exit value of $139M (93.1% gross upside, net 73.1% after 20% dilution).
Multiple converges to 7.5x, exit value $104M (44.8% gross, 24.8% net); growth sustains but no catalytic event.
Multiple compresses to 4x due to intense competition and regulatory headwinds, exit value $55.6M (-22.8% gross, -42.8% net); preference stack not triggered but heavy dilution hurts.
Preference Stack Risk
severeFunding Intensity
31%Total preferred funding $22.4M represents 31% of estimated $72M valuation, creating significant overhang in a downside scenario.
Dilution Risk
highWith no profitability and limited runway, a future round likely dilutes common equity by 15-25%.
Secondary Liquidity
noneNo secondary trading data available; equity illiquid until exit.
Other — 4 roles
- Account Development Rep II · Remote
- Account Manager- Expansion · North America
- Lead Product Designer · Remote Europe
- +1 more →
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on UserGems's data — designed to show you've done your homework.
- 1
“How does UserGems differentiate from ZoomInfo’s similar offering?”
- 2
“What is the path to profitability given current burn rate?”
- 3
“How does the company address GDPR/CCPA compliance for its contact tracking?”
Community
Valuation Sentiment
Our model estimates +4% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.